 | | Vol. 8.38 – 7 October, 2020 |
| |
|
|
| Investigators showed that some members of the family Matonaviridae could cross substantial barriers between host species and that rubella virus probably has a zoonotic origin.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Extrafollicular activation correlated strongly with large antibody-secreting cell expansion and early production of high concentrations of SARS-CoV-2-specific neutralizing antibodies.
[Nature Immunology] |
|
|
|
| Researchers uncovered that NRF2 agonists 4-octyl-itaconate and the clinically approved dimethyl fumarate induced a cellular antiviral program that potently inhibited replication of SARS-CoV2 across cell lines.
[Nature Communications] |
|
|
|
| The authors report 33 distinct 8-mer/9-mer peptides that were identical between SARS-CoV-2 and the human reference proteome. They benchmarked this observation against other viral–human 8-mer/9-mer peptide identity, which suggests generally similar extents of molecular mimicry for SARS-CoV-2 and many other human viruses.
[Cell Death Discovery] |
|
|
|
| Researchers mapped immunogenic epitopes present on the four structural proteins of SARS-CoV-2 and we designed a multi-epitope peptide based vaccine that, demonstrated a high immunogenic response with a vast application on world’s human population.
[Scientific Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists demonstrated that, like humans, Dock8−/− mice have a profound type 2 CD4+ helper T cell bias upon pulmonary infection with Cryptococcus neoformans and other non-TH2 stimuli.
[Nature Immunology] |
|
|
|
| Epigenomic and transcriptomic analyses of regions near highly induced genes in natural killer (NK) cells both in vitro and in a model of Toxoplasma gondii infection revealed de novo chromatin accessibility and enhancer remodeling controlled by signal-regulated transcription factors STATs.
[Immunity] |
|
|
|
| Researchers studied whether phagosomes regulated their size to preserve integrity during infection with the fungal pathogen Candida albicans.
[Cell Host & Microbe] |
|
|
|
| Investigators used subvolume refinement to achieve a 3.4 Å resolution structure and identified two distinct lipid moieties. The first arose from the inner leaflet and was coordinated by hydrophobic residues of the M and E transmembrane helices that form a binding pocket not previously characterized.
[Nature Communications] |
|
|
|
| Scientists demonstrated that the minimal Pmt unit necessary for phenol-soluble modulin export was PmtCD and provided its first atomic characterization by single-particle cryo-EM and x-ray crystallography. They have captured the transporter in the ATP-bound state at near atomic resolution, revealing a type II ABC exporter fold, with an additional cytosolic domain.
[Science Advances] |
|
|
|
| The authors assessed whether multilineage mesenchymal stem cells, best known for immunomodulation toward T cells, could be therapeutic for highly virulent bacterial infections via modulation of polymorphonuclear neutrophils.
[Cell Reports] |
|
|
|
| Scientists investigated the patterns of T cell escape variants in the replication-competent reservoir of 25 persons living with HIV-1 durably suppressed on ART.
[eLife] |
|
|
|
|
| Scientists describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses.
[Nature Reviews Microbiology] |
|
|
|
| Researchers discuss heterogeneity in entry receptors, followed by a discussion on error-prone and low-fidelity polymerases and their impact on viral diversity.
[Nature Reviews Microbiology] |
|
|
|
| The authors discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.
[Nature Cancer] |
|
|
|
|
| Revelation Biosciences, Inc. announced that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase I clinical study of REVTx-99 in healthy volunteers. HREC approval permitted Revelation to complete the required Clinical Trial Notification to the Therapeutic Goods Administration. REVTx-99 is in development as an early treatment for SARS-CoV-2 Infection.
[Revelation Biosciences, Inc. (BusinessWire, Inc.)] |
|
|
|
| Vedanta Biosciences announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 million, from the Biomedical Advanced Research and Development Authority to advance clinical development of VE303 for high-risk Clostridioides difficile infection.
[Vedanta Biosciences, Inc.] |
|
|
|
|
| December 2 – December 4
Virtual |
|
|
|
|
|
| | Rheinische Friedrich-Wilhelms-Universität – Bonn, Germany |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
